The recent clinical trial of losmapimod for the treatment of facioscapulohumeral muscular dystrophy.
Bloch RJ, Traficante M, Mariot V, Dumonceaux J.
Neuromuscul Disord · research-article; review; journal article · DOI 10.1016/j.nmd.2025.105422 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för losmapimod. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
28 träffarThe participants' perspective on facioscapulohumeral muscular dystrophy trials in The Netherlands - A qualitative study.
Stinissen L, Kools J, Bouma S, Lenssen E, Sanders E, Lanser A, de Haas R, van Engelen BG, Oortwijn W, Voermans NC.
J Neuromuscul Dis · research-article; journal article · DOI 10.1177/22143602241313117Losmapimod ameliorates doxorubicin-induced cardiotoxicity through attenuating senescence and inflammatory pathways.
Dabour MS, Abdelgawad IY, Sadaf B, Daniel MR, Grant MKO, Seelig D, Zordoky BN.
Biomed Pharmacother · research-article; journal article · DOI 10.1016/j.biopha.2024.117288Pirfenidone Prevents Heart Fibrosis during Chronic Chagas Disease Cardiomyopathy.
Silva TA, Thomas D, Siqueira-Neto JL, Calvet CM.
Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms25137302An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1.
Kools J, Voermans N, Jiang JG, Mitelman O, Mellion ML, Ramana V, van Engelen BGM.
J Neurol Sci · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1016/j.jns.2024.123096Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
Tawil R, Wagner KR, Hamel JI, Leung DG, Statland JM, Wang LH, Genge A, Sacconi S, Lochmüller H, Reyes-Leiva D, Diaz-Manera J, Alonso-Perez J, Muelas N, Vilchez JJ, Pestronk A, Gibson S, Goyal NA, Hayward LJ, Johnson N, LoRusso S, Freimer M, Shieh PB, Subramony SH, van Engelen B, Kools J, Leinhard OD, Widholm P, Morabito C, Moxham CM, Cadavid D, Mellion ML, Odueyungbo A, Tracewell WG, Accorsi A, Ronco L, Gould RJ, Shoskes J, Rojas LA, Jiang JG.
Lancet Neurol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1474-4422(24)00073-5Comparison of Quantitative Mass Spectrometric Methods for Drug Target Identification by Thermal Proteome Profiling.
George AL, Sidgwick FR, Watt JE, Martin MP, Trost M, Marín-Rubio JL, Dueñas ME.
J Proteome Res · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jproteome.3c00111Antinociceptive properties of losmapimod in two acute pain models in rats: behavioural analysis, immunohistochemistry, dose response, and comparison with usual analgesic drugs.
Soued M, Hamdi L, Ben Rehouma M, Mazoit JX, Benhamou D.
BJA Open · research-article; journal article · DOI 10.1016/j.bjao.2022.100029Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement.
Mellion ML, Ronco L, Berends CL, Pagan L, Brooks S, van Esdonk MJ, van Brummelen EMJ, Odueyungbo A, Thompson LA, Hage M, Badrising UA, Raines S, Tracewell WG, van Engelen B, Cadavid D, Groeneveld GJ.
Br J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1111/bcp.14884Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis.
Gipson DS, Hladunewich MA, Lafayette R, Sedor JR, Rovin BH, Barbour SJ, McMahon A, Jennette JC, Nachman PH, Willette RN, Paglione M, Gao F, Ross Terres JA, Vallow S, Holland MC, Thorneloe KS, Sprecher DL.
Kidney Int Rep · research-article; journal article · DOI 10.1016/j.ekir.2020.05.024Losmapimod Protected Epileptic Rats From Hippocampal Neuron Damage Through Inhibition of the MAPK Pathway.
Li M, Cui L, Feng X, Wang C, Zhang Y, Wang L, Ding Y, Zhao T.
Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2019.00625Identification of a clinical compound losmapimod that blocks Lassa virus entry.
Zhang X, Yan F, Tang K, Chen Q, Guo J, Zhu W, He S, Banadyga L, Qiu X, Guo Y.
Antiviral Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.antiviral.2019.03.014Effects of Anti-Inflammatory Medications in Patients With Coronary Artery Disease: A Focus on Losmapimod.
Tun B, Frishman WH.
Cardiol Rev · review; journal article · DOI 10.1097/crd.0000000000000176The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
Fisk M, Cheriyan J, Mohan D, Forman J, Mäki-Petäjä KM, McEniery CM, Fuld J, Rudd JHF, Hopkinson NS, Lomas DA, Cockcroft JR, Tal-Singer R, Polkey MI, Wilkinson IB.
PLoS One · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1371/journal.pone.0194197Losmapimod: A Novel Clinical Drug to Overcome Gefitinib-Resistance.
Nishimura Y.
EBioMedicine · comment; discussion; journal article · DOI 10.1016/j.ebiom.2018.01.019Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.
Yeung YT, Yin S, Lu B, Fan S, Yang R, Bai R, Zhang C, Bode AM, Liu K, Dong Z.
EBioMedicine · research-article; journal article · DOI 10.1016/j.ebiom.2018.01.017Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
Pascoe S, Costa M, Marks-Konczalik J, McKie E, Yang S, Scherbovsky PS.
Respir Med · clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.rmed.2017.07.002Losmapimod does not reduce cardiovascular events in patients with acute myocardial infarction.
Aronow WS, Kaple RK.
J Thorac Dis · comment; editorial · DOI 10.21037/jtd.2016.08.53Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA, LATITUDE-TIMI 60 Investigators.
JAMA · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1001/jama.2016.3609Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod.
Kragholm K, Newby LK, Melloni C.
Drug Des Devel Ther · video-audio media; review-article; review; journal article · DOI 10.2147/dddt.s69546Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.
Ino H, Takahashi N, Terao T, Igarashi H, Sarai N.
Clin Pharmacol Drug Dev · clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/cpdd.190Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimod.
Barbour AM, Magee M, Shaddinger B, Arya N, Tombs L, Tao W, Patel BR, Fossler MJ, Glaser R.
J Clin Pharmacol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1002/jcph.465Acute coronary syndromes: Promising data for losmapimod in NSTEMI.
Roberts A.
Nat Rev Cardiol · comment; journal article · DOI 10.1038/nrcardio.2014.96Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
Inamdar A, Merlo-Pich E, Gee M, Makumi C, Mistry P, Robertson J, Steinberg E, Zamuner S, Learned S, Alexander R, Ratti E.
J Psychopharmacol · multicenter study; randomized controlled trial; journal article · DOI 10.1177/0269881114529377Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.
Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J.
Br J Clin Pharmacol · comparative study; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1111/bcp.12063[Losmapimod: a novel drug against cardiovascular diseases?].
Dewenter M, Vettel C, El-Armouche A.
Dtsch Med Wochenschr · review; journal article; english abstract · DOI 10.1055/s-0032-1327368The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.
Melloni C, Sprecher DL, Sarov-Blat L, Patel MR, Heitner JF, Hamm CW, Aylward P, Tanguay JF, DeWinter RJ, Marber MS, Lerman A, Hasselblad V, Granger CB, Newby LK.
Am Heart J · clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.ahj.2012.07.030Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
Willette RN, Eybye ME, Olzinski AR, Behm DJ, Aiyar N, Maniscalco K, Bentley RG, Coatney RW, Zhao S, Westfall TD, Doe CP.
J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.109.154443